Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Intensive glucose lowering has previously been shown to increase mortality among persons with advanced type 2 diabetes and a high risk of cardiovascular disease. This report describes the 5-year outcomes of a mean of 3.7 years of intensive glucose lowering on mortality and key cardiovascular events. METHODS: We randomly assigned participants with type 2 diabetes and cardiovascular disease or additional cardiovascular risk factors to receive intensive therapy (targeting a glycated hemoglobin level below 6.0%) or standard therapy (targeting a level of 7 to 7.9%). After termination of the intensive therapy, due to higher mortality in the intensive-therapy group, the target glycated hemoglobin level was 7 to 7.9% for all participants, who were followed until the planned end of the trial. RESULTS: Before the intensive therapy was terminated, the intensive-therapy group did not differ significantly from the standard-therapy group in the rate of the primary outcome (a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) (P=0.13) but had more deaths from any cause (primarily cardiovascular) (hazard ratio, 1.21; 95% confidence interval [CI], 1.02 to 1.44) and fewer nonfatal myocardial infarctions (hazard ratio, 0.79; 95% CI, 0.66 to 0.95). These trends persisted during the entire follow-up period (hazard ratio for death, 1.19; 95% CI, 1.03 to 1.38; and hazard ratio for nonfatal myocardial infarction, 0.82; 95% CI, 0.70 to 0.96). After the intensive intervention was terminated, the median glycated hemoglobin level in the intensive-therapy group rose from 6.4% to 7.2%, and the use of glucose-lowering medications and rates of severe hypoglycemia and other adverse events were similar in the two groups. CONCLUSIONS: As compared with standard therapy, the use of intensive therapy for 3.7 years to target a glycated hemoglobin level below 6% reduced 5-year nonfatal myocardial infarctions but increased 5-year mortality. Such a strategy cannot be recommended for high-risk patients with advanced type 2 diabetes. (Funded by the National Heart, Lung and Blood Institute; ClinicalTrials.gov number, NCT00000620.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those levels predict the risk of cardiovascular disease.”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Diabetic kidney disease might also play a role in the arrhythmia-associated mechanism of sudden death in this setting.655”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [655]
Experimental — accuracy not yet measuredIn the citing paper
“However, the belief that HbA1c was a surrogate marker was contradicted by findings from the ACCORD trial that diabetics randomly assigned to intensive treatment that reduced HbA1c levels in fact increased the risk of CVD events [14].”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
In the citing paper
“For example, intensive hypoglycemic treatments, such as oral hypoglycemics and insulin, substantially reduce fasting glucose and HbA1c levels.”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
In the citing paper
“Similar U-shaped curves were found in a 7-year observational study of persons with T1D and a 22-year observational study of >20,000 persons with T2D.83,84”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Self-citationEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Self-citationGlycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults
Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908359 · Cited by 1,544
Huxley, R., Barzi, F., & Woodward, M. (2006) · BMJ · doi:10.1136/bmj.38678.389583.7c · Cited by 1,534
The J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
Gerstein, H. C., Miller, M., & Byington, R. P. (2010) · Cited by 981
Bonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933
Miller, M. E., Bonds, D. E., Gerstein, H. C., Seaquist, E. R., Bergenstal, R. M., Calles-Escandon, J., Childress, R. D., Craven, T. E., Cuddihy, R. M., Dailey, G., et al. (2010) · BMJ · doi:10.1136/bmj.b5444 · Cited by 429
Cited by
Items 501–600 of 1,000
Sriphrapradang, C., Thewjitcharoen, Y., Buranapin, S., Sawanyawisuth, K., Yenseung, N., Ubonchareon, W., Limpijankit, L., & Himathongkam, T. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1808454 · Cited by 15
Müller, J. E., Sträter-Müller, D., Marks, H.-J., Gläsner, M., Kneppe, P., Clemens-Harmening, B., & Menker, H. (2011) · Nutrition & Metabolism · doi:10.1186/1743-7075-8-92 · Cited by 16
Kim, H. M., Lim, J. S., Lee, B., Kang, E. S., Lee, H. C., & Soo, B. (2015) · Endocrinology and Metabolism · doi:10.3803/enm.2015.30.1.84 · Cited by 14
Therapeutic Targeting of Cellular Stress to Prevent Cardiovascular Disease: A Review of the Evidence
Mooradian, A. D. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0199-7 · Cited by 15
Glycaemic control and treatment of type 2 diabetes in adults aged 75 years or older
Rodríguez‐Poncelas, A., Barrot, J., de Tuero, G. C., López-Arpí, C., Vlacho, B., López‐Simarro, F., Mundet, X., & Franch‐Nadal, J. (2018) · International Journal of Clinical Practice · doi:10.1111/ijcp.13075 · Cited by 14
Systemic Therapies for Diabetic Retinopathy
Frank, R. N. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.08.019 · Cited by 14
Shah, M. U., Roebuck, A., Srinivasan, B., Ward, J. K., Squires, P. E., Hills, C. E., & Lee, K. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1499681 · Cited by 24
Huelgas, R. G., Peralta, F. G., Fernández, L. C., Galve, E., Casanueva, F. F., Puig‐Domingo, M., Bravo, J. J. M., Orozco‐Beltrán, D., Muñoz, J. E., Torre, E. L. M., et al. (2015) · Revista Clínica Española · doi:10.1016/j.rce.2015.07.003 · Cited by 21
Ike, A., Shirai, K., Nishikawa, H., Iwata, A., Yahiro, E., Sugihara, M., Kawamura, A., Uehara, Y., Zhang, B., Ogawa, M., et al. (2014) · Journal of Cardiology · doi:10.1016/j.jjcc.2014.06.012 · Cited by 14
“Further, in the ACCORD trial [20], while follow-up was discontinued after 3.”
MethodAwareness Level of Hypoglycemia Among Diabetes Mellitus Type 2 Patients in Al Qassim Region
AlTowayan, A., Alharbi, S., Aldehami, M., Albahli, R., Alnafessah, S., & Alharbi, A. M. (2023) · Cureus · doi:10.7759/cureus.35285 · Cited by 19
“It is difficult to achieve optimal blood glucose control since it involves the necessity for glycemic control with the risk of hypoglycemia [23,24].”
Bouhanick, B., Barigou, M., Kantambadouno, J.-B., & Chamontin, B. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.02.315 · Cited by 14
“Dans cette seconde partie d’étude, alors que l’hémoglobine glyquée du groupe intensif passe de 6,4 à 7,2 %, le taux d’hypoglycémies sévères devient comparable entre les deux groupes [28].”
BackgroundDai, J., Krasnow, R. E., Liu, L., Sawada, S. G., & Reed, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069332 · Cited by 15
“This review [40] included three recent large-scale randomized trials among type 2 diabetic patients [41,42,43], one follow-up study after the intervention trials among type 2 diabetic patients [44], and one after-trial follow-up study among type 1 diabetic patients [45].”
BackgroundClinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 2
Arps, K. E., Pallazola, V. A., Cardoso, R. N., Meyer, J., Jones, R., Latina, J. M., Gluckman, T. J., Stone, N. J., Blumenthal, R. S., & McEvoy, J. W. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.01.031 · Cited by 14
Piatti, P. M., Marone, E. M., Mantero, M., Setola, E., Galluccio, E., Lucotti, P., Shehaj, E., Villa, V., Perticone, F., Venturini, M., et al. (2012) · Acta Diabetologica · doi:10.1007/s00592-012-0426-x · Cited by 14
HLA class I and II alleles are associated with microvascular complications of type 1 diabetes
Lipner, E. M., Tomer, Y., Noble, J. A., Monti, M. C., Lonsdale, J. T., Corso, B., Stewart, W. C. L., & Greenberg, D. A. (2013) · Human Immunology · doi:10.1016/j.humimm.2013.01.013 · Cited by 13
“Previous work has established that reducing blood glucose concentrations close to normal glycemic ranges also significantly reduces the incidence of diabetes-associated complications (although, in a recent study of T2D, tight control appears to increase mortality [47,48]).”
Hypoglycemia and Cardiovascular Disease: Lessons from Outcome Studies
Pistrosch, F., & Hanefeld, M. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0678-2 · Cited by 14
Severe hypoglycemia in the Look AHEAD Trial
Greenway, F. L. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.03.016 · Cited by 13
Miyake, H., Kanazawa, I., & Sugimoto, T. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0076 · Cited by 13
Inflammation reprogramming and immunomodulation: Next-generation treatments for atherosclerosis
Choudhury, R. P., Hargreaves, R., Chai, J., & Fisher, E. A. A. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102288 · Cited by 15
Ağraz, M., Deng, Y., Karniadakis, G. E., & Mantzoros, C. S. (2024) · Scientific Reports · doi:10.1038/s41598-024-69844-z · Cited by 18
Aktuelle Therapie des Typ-2-Diabetes
Schernthaner, G., & Schernthaner, G.-H. (2012) · Der Internist · doi:10.1007/s00108-012-3203-6 · Cited by 12
Chhabra, L., Liti, B., Kuraganti, G., Kaul, S., & Trivedi, N. (2013) · International Journal of Endocrinology · doi:10.1155/2013/856793 · Cited by 16
for the ACCORD Group of Investigators, Punthakee, Z., Miller, M. E., Simmons, D. L., Riddle, M. C., Ismail‐Beigi, F., Brillon, D. J., Bergenstal, R. M., Savage, P. J., HRAMIAK, I. M., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3318-5 · Cited by 13
“2% in the group randomised to standard care [11].”
BackgroundCardiovascular Outcome Trials of the Incretin-Based Therapies: What Do We Know So Far?
Mora, P. F., & Johnson, E. L. (2016) · Endocrine Practice · doi:10.4158/ep161481.ra · Cited by 12
Strategies for the Prevention of Coronary Artery Disease Complications: Can We Do Better?
Ambrose, J. A., & Najafi, A. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.04.006 · Cited by 13
Hunt, L. M., Arndt, E., Bell, H. S., & Howard, H. (2021) · Journal of Bioethical Inquiry · doi:10.1007/s11673-021-10119-x · Cited by 13
Shi, S., Gouskova, N., Najafzadeh, M., Wei, L., & Kim, D. H. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-050335 · Cited by 13
Cardoso, C. R. L., Leite, N. C., & Salles, G. F. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108124 · Cited by 13
Uemura, F., Okada, Y., Mita, T., Torimoto, K., Wakasugi, S., Katakami, N., Yoshii, H., Matsushita, K., Nishida, K., Inokuchi, N., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0465 · Cited by 15
Abbatecola, A. M., Bo, M., Armellini, F., D'Amico, F., Desideri, G., Falaschi, P., Greco, A., Guerrini, G., Lattanzio, F., Volpe, C., et al. (2015) · Metabolism · doi:10.1016/j.metabol.2015.07.018 · Cited by 12
“Patients had a mean age [SD] = 82 [8] years; BMI = 25.”
BackgroundDiscontinuation of Unnecessary Medications in Older Adults
Brandt, N., & Stefanacci, R. G. (2011) · The Consultant Pharmacist · doi:10.4140/tcp.n.2011.845 · Cited by 14
Glycemic Variability and Glycemic Control in the Acutely Ill Cardiac Patient
Moore, J., & Dungan, K. M. (2012) · Heart Failure Clinics · doi:10.1016/j.hfc.2012.06.006 · Cited by 14
“diagnosed diabetes.(49,50) However, it is unclear if these observations can be extended to acute hyperglycemia associated with acute illness.”
Kritchevsky, S. B., & Williamson, J. D. (2014) · The journal of nutrition health & aging · doi:10.1007/s12603-014-0456-x · Cited by 12
Lehrke, M., Leiter, L. A., Hehnke, U., Thiemann, S., Bhandari, A., Meinicke, T. W., & Johansen, O. E. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.06.015 · Cited by 13
Physician perspectives on de-intensifying diabetes medications
Genere, N., Sargis, R. M., Masi, C. M., Nathan, A. G., Quinn, M. T., Huang, E. S., & Laiteerapong, N. (2016) · Medicine · doi:10.1097/md.0000000000005388 · Cited by 12
“Physicians that do not individualize goals may pursue overly aggressive treatments with uncertain benefits and potential harm.([5,15,17]) We also found that physicians considered several different predefined HbA1C thresholds when deciding to initiate conversations about medication de-intensification.”
BackgroundThe Role of Diet in the Prevention and Treatment of Cardiovascular Disease
Richter, C. K., Skulas‐Ray, A. C., & Kris‐Etherton, P. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802928-2.00027-8 · Cited by 15
Patoulias, D., Stavropoulos, K., Imprialos, K. P., Athyros, V. G., Doumas, M. N., & Karagiannis, A. I. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190426162746 · Cited by 13
Nyström, T., Holzmann, M. J., & Sartipy, U. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002411 · Cited by 13
Insulin-Induced Hypoglycemia and Its Effect on the Brain
Herzog, R. I., Sherwin, R. S., & Rothman, D. L. (2011) · Diabetes · doi:10.2337/db11-0498 · Cited by 12
HbA1c measurement and relationship to incident stroke
Robson, R. A., Lacey, A., Luzio, S. D., van Woerden, H. C., Heaven, M. L., Wani, M., Halcox, J., Castilla‐Guerra, L., Dawson, J., & Hewitt, J. (2015) · Diabetic Medicine · doi:10.1111/dme.13057 · Cited by 13
Type 2 Diabetes Prevention: Implications of Hemoglobin A1c Genetics
Leong, A., & Meigs, J. B. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.351 · Cited by 15
Al‐Salameh, A., Bucher, S., Bauduceau, B., Benattar‐Zibi, L., Berrut, G., Bertin, P., Corruble, E., Danchin, N., Dérumeaux, G., Doucet, J., et al. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.08.248 · Cited by 13
Cardiovascular Safety of Antihyperglycemic Agents: “Do Good or Do No Harm”
Manolis, A. S., Manolis, T. A., & Manolis, A. S. (2018) · Drugs · doi:10.1007/s40265-018-0985-4 · Cited by 12
Shao, H., Lin, J., Zhuo, X., Rolka, D. B., Gregg, E. W., & Zhang, P. (2019) · Diabetes Care · doi:10.2337/dc19-0381 · Cited by 15
The Complex Nature of Knowledge
Sturmberg, J. P., & Miles, A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4998-0_4 · Cited by 12
Fibrate Pharmacogenomics: Expanding Past the Genome
House, J. S., & Motsinger‐Reif, A. A. (2020) · Pharmacogenomics · doi:10.2217/pgs-2019-0140 · Cited by 12
Ghaith, N., Malaeb, B., Itani, R., Alnafea, M. A., & Faraj, A. A. (2021) · Diagnostics · doi:10.3390/diagnostics11050789 · Cited by 12
“8 mmol/L after two hours following a meal) is not only challenging but also not recommended for diabetic patients [19].”
BackgroundInfluentialOverview of the Guidelines and Evidence for the Pharmacologic Management of Type 2 Diabetes Mellitus
Liday, C. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.12.37s · Cited by 11
“nonfatal stroke, or death from cardiovascular causes.(21) The intensive-treatment group continued to have more deaths from any cause (primarily cardiovascular) but fewer nonfatal myocardial infarctions.”
BackgroundDiabetes Control Among Hispanics in the Action to Control Cardiovascular Risk in Diabetes Trial
Getaneh, A., Light, L. S., Brillon, D. J., Escandón, J. C., Felicetta, J. V., Evans, G. W., Lopez-Jimenez, C., Cuddihy, R. M., & Bigger, J. T. (2012) · Journal of General Internal Medicine · doi:10.1007/s11606-012-2131-4 · Cited by 12
Incidence and risk factors of hypoglycemia among Type 2 diabetic patients in a South Indian hospital
Vikas, P., Chandrakumar, A., Dilip, C., Suriyaprakash, T. N. K., Thomas, L., & Surendran, R. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.01.014 · Cited by 12
“It has been postulated that hypoglycemia may increase the risk associated with acute coronary syndromes and increase the mortality in post-MI patients [20].”
BackgroundMetabolomic patterns associated to QTc interval in shiftworkers: an explorative analysis
Campagna, M., Locci, E., Piras, R., Noto, A., Lecca, L. I., Pilia, I., Cocco, P., d’Aloja, E., & Scano, P. (2016) · Biomarkers · doi:10.3109/1354750x.2016.1171900 · Cited by 11
Lee, E. K. P. (2016) · Hong Kong Medical Journal · doi:10.12809/hkmj154737 · Cited by 11
Kosiborod, M. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.08.017 · Cited by 13
Multifactorial intervention for diabetes control among older users of insulin
Machry, R. V., Pedroso, H. U., Vasconcellos, L. D. S., Nunes, R. R., Evaldt, C. D. A., Filho, E. B. Y., & Rodrigues, T. D. C. (2018) · Revista de Saúde Pública · doi:10.11606/s1518-8787.2018052000144 · Cited by 14
Novel ABCA1 peptide agonists with antidiabetic action
Azhar, S., Bittner, S., Hu, J., Shen, W., Cortez, Y., Xiao, H., Han, L., Lagerstedt, J. O., Kraemer, F. B., & Johansson, J. O. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.09.011 · Cited by 11
Therapy to Obese Type 2 Diabetes Mellitus: How Far Will We Go Down the Wrong Road?
Heng, X.-P., Li, X., Li, L., Yang, L., Wang, Z.-T., & Huang, S.-P. (2018) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-018-3053-8 · Cited by 11
Derosa, G., Catena, G., Scelsi, L., D’Angelo, A., Raddino, R., Cosentino, E. R., Maggi, A., Pasini, G., Borghi, C., & Maffioli, P. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3219 · Cited by 11
“5 years increased mortality and did not significantly reduce major cardiovascular events (CV) in type 2 diabetes mellitus.(2) This can be due to the fact that, other than reaching an optimal glycaemic control, we have to avoid hypoglycaemia, a common, unpredictable, and potentially dangerous side effect of antidiabeti…”
BackgroundMotivational Strategies to Prevent Frailty in Older Adults with Diabetes: A Focused Review
Vaccaro, J. A., Gaillard, T. R., Huffman, F. G., & Vieira, E. R. (2019) · Journal of Aging Research · doi:10.1155/2019/3582679 · Cited by 15
“7 years compared with the 7-8% standard target, resulting in discontinuation of the treatment in all groups [24].”
MethodPredicted lean body mass, fat mass, and heart failure in patients with type 2 diabetes mellitus
Tang, X., Zhu, Y., & Xing, Z. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.12.008 · Cited by 11
Clinical practice and implications of recent diabetes trials
Webster, M. W. I. (2011) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328347b139 · Cited by 12
Yunn, N.-O., Kim, J. J., Kim, Y., Leibiger, I. B., Berggren, P., & Ryu, S. H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.005 · Cited by 11
Glucose-lowering treatment in cardiovascular and peripheral artery disease
Suades, R., Cosentino, F., & Badimón, L. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.03.001 · Cited by 12
Edetate Disodium-Based Treatment for Secondary Prevention in Post-Myocardial Infarction Patients
Lamas, G. A., & Issa, O. (2016) · Current Cardiology Reports · doi:10.1007/s11886-015-0690-9 · Cited by 10
Lyngsie, P. J., Lopes, S. H. K., & Olsen, J. (2016) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.15.68 · Cited by 10
Population-Based Strategy for Preventing Diabetes and its Complications
Watanabe, S. (2018) · Diabetes Research - Open Journal · doi:10.17140/droj-4-e011 · Cited by 10
Development and Validation of the Real-World Progression in Diabetes (RAPIDS) Model
Basu, A., Sohn, M., Bartle, B., Chan, K. C. G., Cooper, J. M., & Huang, E. S. (2019) · Medical Decision Making · doi:10.1177/0272989x18817521 · Cited by 10
Evidence-Based Diagnosis: An Introduction to Clinical Epidemiology
Newman, T. B., & Kohn, M. A. (2020) · Cited by 10
Depression is associated with heart failure in patients with type 2 diabetes mellitus
Chen, Y., Chen, L., & Xing, Z. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1181336 · Cited by 11
“A central committee adjudicated the HF events according to a predefined protocol (5, 13, 14).”
BackgroundMethodTorre, C., Guerreiro, J., Romano, S., Miranda, A., Longo, P., Alão, S., Conceição, J., & Laires, P. A. (2018) · Primary care diabetes · doi:10.1016/j.pcd.2018.06.001 · Cited by 10
Crutzen, S., van den Born-Bondt, T., Denig, P., & Taxis, K. (2021) · BMC Family Practice · doi:10.1186/s12875-021-01466-0 · Cited by 18
Abbaszadeh, S., Shafiee, A., Bina, P., Jalali, A., Sadeghian, S., & Karimi, A. (2017) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000103 · Cited by 10
Trends in the incidence of use of noninsulin glucose‐lowering drugs between 2006 and 2013 in France
Arnaud, M., Bezin, J., Bégaud, B., Pariente, A., & Salvo, F. (2017) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12298 · Cited by 11
Lee, E. K. P. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12704 · Cited by 10
Inzucchi, S. E., & Sherwin, R. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00237-2 · Cited by 10
Fuentes, B., Amaro, S., Alonso de Leciñana, M., Arenillas, J. F., Ayo-Martín, O., Castellanos, M., Freijo, M., García-Pastor, A., Gomis, M., Gómez Choco, M., et al. (2021) · Neurología · doi:10.1016/j.nrl.2020.04.030 · Cited by 9
Herrmann, K., Shan, K., Brunell, S. C., & Chen, S. (2014) · Endocrine Practice · doi:10.4158/ep13477.or · Cited by 9
Koshizaka, M., Green, J. B., & Alexander, J. H. (2012) · Circulation Journal · doi:10.1253/circj.cj-12-0428 · Cited by 10
Khunti, K., Damcı, T., Husemoen, L. L. N., Babu, V., & Liebl, A. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.11.028 · Cited by 11
Scheen, A. J. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.10.023 · Cited by 9
da Motta, A. A. L., Bonanomi, M. T. B. C., Ferraz, D., Preti, R. C., Sophie, R., Abalem, M. F., Queiroz, M. S., Pimentel, S. L. G., Takahashi, W. Y., & Damico, F. M. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.02.002 · Cited by 9
Kianmehr, H., Guo, J. S., Lin, Y., Luo, J., Cushman, W. C., Shi, L., Fonseca, V. A., & Shao, H. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108287 · Cited by 12
Murray, D. M., Kaplan, R. M., Ngo‐Metzger, Q., Portnoy, B., Olkkola, S., Stredrick, D. L., Kuczmarski, R. J., Goldstein, A. B., Perl, H. I., & O’Connell, M. E. (2015) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2015.04.024 · Cited by 9
Liu, F., Wu, M. C., Feng, Y., Zhong, H., Cui, T., Huang, Y., Liang, Y., Diao, Y., Zang, L., Li, L., et al. (2013) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1300030 · Cited by 11
Lewis, C. E., Bantle, J. P., Bertoni, A. G., Blackburn, G. L., Brancati, F. L., Bray, G. A., Cheskin, L. J., Curtis, J. M., Egan, C., Evans, M. E., et al. (2020) · Obesity · doi:10.1002/oby.22676 · Cited by 10
“This is consistent with the findings for nonfatal acute MI in pharmacologic trials of tight glycemic control in type 2 diabetes, including ACCORD (17), the trial phase of the UK Prospective Diabetes Study (18), and Obesity www.obesityjournal.org Obesity | VOLUME 28 | NUMBER 2 | FEBRUARY 2020 255”
ResultChanges in fat mass and lean body mass and outcomes in type 2 diabetes mellitus
Xing, Z., & Chai, X. (2022) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02916-4 · Cited by 10
“The secondary endpoints were the individual component of MACEs including cardiac death, non-fatal MI, and non-fatal stroke [10, 11].”
BackgroundEffects of glucose and blood pressure reduction on subclinical cardiac damage: Results from ADVANCE
Juraschek, S. P., Wang, D., McEvoy, J. W., Harrap, S. B., Harris, K., Mancia, G., Marre, M., Neal, B. C., Patel, A. A., Poulter, N. R., et al. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.04.044 · Cited by 10
Júnior, C. R. B., Bano, A., Tang, Y., Sun, X., Abate, A., Hall, E., Mitri, J., Morieri, M. L., Shah, H., & Doria, A. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01869-6 · Cited by 12
Type 2 Diabetes: Etiology, Epidemiology, Pathogenesis, and Treatment
Burns, C., & Francis, N. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_34 · Cited by 13
Litke, R. R., Moulin, S., Cordonnier, C., Fontaine, P., & Leys, D. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7874-5 · Cited by 10
Davis, S. N. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.864950 · Cited by 9
Managing Special Populations Among Patients with Type 2 Diabetes Mellitus
Marquess, J. G. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.12.65s · Cited by 9
“35–37 The Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial studied adults with type 2 diabetes at high risk for cardiovascular disease.(38) Patients received either intensive therapy (A1C target < 6.”
BackgroundNew Concepts in the Diagnosis and Non-Surgical Treatment of Cardiovascular Disease
Houston, M. C. (2013) · Internal Medicine Open Access · doi:10.4172/2165-8048.s11-002 · Cited by 9
Wu, W., Sun, Z., Li, Q., Wang, M., Miao, J., Zheng, Z., Sun, L., Huang, J., Wang, Y., Zhang, H., et al. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.02.010 · Cited by 11
Birkhead, J. S., Weston, C. F. M., Timmis, A., & Chen, R. (2014) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872614549733 · Cited by 10
Diabetes, Obesity and Atrial Fibrillation: Epidemiology, Mechanisms and Interventions.
Asghar, O., Alam, U., Hayat, S., Aghamohammadzadeh, R., Heagerty, A. M., & Malik, R. A. (2013) · Europe PMC (PubMed Central) · doi:10.4022/jafib.869 · Cited by 9
Cardiovascular safety of therapies for type 2 diabetes
Gupta, P. K., & White, W. B. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1239707 · Cited by 10
“Theoretical concerns, such as increased rates of hypoglycemia [4,9] and stimulation of the sympathetic nervous system in patients on both ACE inhibitors and DPP-4 inhibitors [50,51], have been proposed but are unlikely to be attributable because no interactions with ACE inhibitors and the DPP-4 inhibitors were seen in…”
BackgroundHorodinschi, R.-N., & Diaconu, C. C. (2021) · Healthcare · doi:10.3390/healthcare9070830 · Cited by 12
Clinical Inertia: A Critique of Medical Reason
Reach, G. (2014) · Springer eBooks · doi:10.1007/978-3-319-09882-1 · Cited by 9
Diabetes and periodontal therapy
Pihlstrom, B. L., & Buse, J. B. (2014) · The Journal of the American Dental Association · doi:10.14219/jada.2014.112 · Cited by 10
Type 2 diabetes: Why should diabetologists and cardiologists work more closely together?
Valensi, P. E., Picard, S., & Pathak, A. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.07.007 · Cited by 9
Metadata
- Authors
- The ACCORD Study Group
- Affiliations
- McMaster University (CA)
- Corresponding author
- The ACCORD Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-03-03
- Volume
- 364
- Issue
- 9
- Pages
- 818-828
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4083508
- OpenAlex
- W2125468958
- Cited by
- 1,035
- References
- 18
- Citations by year
- 2026: 12 · 2025: 33 · 2024: 27 · 2023: 35 · 2022: 29 · 2021: 61 · 2020: 51 · 2019: 53 · 2018: 81 · 2017: 78 · 2016: 80 · 2015: 91 · 2014: 100 · 2013: 108 · 2012: 120
- FWCI
- 104.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, n01hc95178-28-0-1, n01hc95179-25-0-0)
- National Heart, Lung, and Blood Institute (N01- HC-95181, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, Y1-HC-9035, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, N01 HC095180, Y01 HC009035, Y1-HC-1010, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, HbA1c, cardiovascular outcomes, mortality, myocardial infarction, stroke, cardiovascular disease, glycemic targets, hypoglycemia, adverse events, long-term follow-up, EXSCEL trial
- MeSH terms
- Adult, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Proportional Hazards Models, Treatment Outcome, Stroke, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.